The estimated Net Worth of David Earp is at least $2.21 million dollars as of 1 June 2012. David Earp owns over 27,155 units of Geron stock worth over $2,051,912 and over the last 21 years David sold GERN stock worth over $158,622.
David has made over 3 trades of the Geron stock since 2011, according to the Form 4 filled with the SEC. Most recently David sold 27,155 units of GERN stock worth $37,202 on 1 June 2012.
The largest trade David's ever made was selling 27,155 units of Geron stock on 1 June 2012 worth over $37,202. On average, David trades about 2,638 units every 18 days since 2003. As of 1 June 2012 David still owns at least 467,406 units of Geron stock.
You can see the complete history of David Earp stock trades at the bottom of the page.
David's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury et Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: